化疗对中晚期非小细胞肺癌患者淋巴细胞亚群的影响
Influence of chemotherapy on lymphocyte subsets in patients with advanced non-small cell lung cancer
徐春华 1于力克 1张宇1
作者信息
- 1. 南京市胸科医院呼吸科,江苏,南京,210029
- 折叠
摘要
目的 探讨NSCLC患者在化疗前后淋巴细胞亚群含量的变化及临床意义.方法 采用流式细胞仪技术,分别对治疗组和对照组外周血淋巴细胞亚群进行检测计数.结果 76例 NSCLC患者 CD3+、CD4+、NK细胞的数量以及 CD4+/CD8+比值均明显低于健康人群,其CD8+细胞的比例明显高于健康人群,差异具有统计学意义( P <0.05).化疗后CD3+、CD4+、CD4+/CD8+、NK较化疗前升高 ( P <0.05);CD8+ 化疗前后差异无统计学意义( P >0.05).结论 NSCLC患者机体的免疫状态与病情发展、临床分期密切相关,化疗可明显改善 NSCLC患者机体的免疫功能.
Abstract
Objective To evaluate the variations of lymphocyte subsets before and after chemotherapy in patients with non-small cell lung cancer (NSCLC). Methods Lymphocyte subsets were determined by flow cytometry in 47 healthy controls and 76 patients with NSCLC before and after chemotherapy. Results Compared with the control group, the mean values of CD3 +, CD4 +, NK and CD4 +/CD8 + ratio were significantly decreased ,and the mean value of CD8 + was significantly increase ( P ＜ 0.05 ) in patients with NSCLC. The values of CD3 +, CD4 +, NK and CD4 +/CD8 + of NSCLC patients were increased after chemotherapy ( P ＜ 0.05 ), but there were no changes in CD8 + percentages ( P ＞ 0.05). Conclusion The immunological status is correlated with the progression and clinical stage of NSCLC and chemotherapy may improve immunological response of patients.
关键词
癌,非小细胞肺/药物疗法/淋巴细胞亚群/药物疗法/肺肿瘤/血液/抗原,CD3/血液/抗原,CD4/血液/抗原,CD8/血液/免疫,细胞/杀伤细胞,天然引用本文复制引用
出版年
2011
国家科技期刊平台
NSTL
维普
万方数据